Company Overview and News

Deals of the day-Mergers and acquisitions

2018-05-23 reuters
May 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Wednesday:

Oil Holds Near 3-Year High Amid Venezuela Sanction Concerns

2018-05-22 rigzone
(Bloomberg) -- Oil settled slightly lower after trading near the highest price in almost 3 1/2 years as new sanctions on Venezuela and shrinking U.S. crude inventories spurred concerns about tightening worldwide supplies.

DHCP / Ditech Holding Corporation - Stock Institutional Ownership and Shareholders -

Ditech Holding Corporation (NYSE:DHCP) has 36 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,937,873 shares. Largest shareholders include Baker Street Capital Management, LLC, Birch Run Capital Advisors, LP, Omega Advisors Inc., First Pacific Advisors, LLC, Centerbridge Partners, L.P., Lion Point Capital, LP, Barclays Plc, Eos Management, L.

Barclays Gets Fund-Raising Charge Clearance From UK Court

2018-05-22 zacks
The U.K’s Crown Court dismissed all the charges brought by the Serious Fraud Office (SFO) against Barclays PLC (BCS - Free Report) , relating to its series of fund raisings from Qatar Holding LLC in 2008. Details of the Fund Raising Back in 2008, during the peak of the financial crisis, Barclays made a series of funding agreements with Qatar Holding. The company raised nearly £12 billion through the sale of its shares to Qatar Holding, particularly in June and October.

Oil rises as Venezuela sanctions stoke crude supply risk concern

2018-05-22 bworldonline
Oil extended gains as a new wave of U.S. sanctions on Venezuela stoked concerns over its crude production and as analysts forecast further declines in American stockpiles.

BlackRock: Wait For A Better Price

2018-05-22 seekingalpha
It offers traditional mutual funds, systematic strategies and ETFs, being therefore well prepared to adapt its business to the changing dynamics in its industry.

Flash - UK court drops charges against Barclays over Qatar funding - France 24

2018-05-22 france24
A British court has dropped criminal charges against Barclays over its emergency fundraising from Qatar during the financial crisis a decade ago, the lender said Monday.

PRESS DIGEST- British Business - May 22

2018-05-21 reuters
May 22 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

Barclays may have been cleared, but scrutiny of its £12bn Qatar cash call will run on

In a statement to investors the high street bank said the Crown Court had dismissed all fraud charges against the lender relating to its £11.8bn emergency cash call at the height of the financial crisis.

BCS / Barclays Bank Plc F-N


PayPal (PYPL) Acquires iZettle, Boosts Competitive Strength

2018-05-21 zacks
In a bid to bolster presence in the payment industry, PayPal Holdings, Inc. (PYPL - Free Report) has acquired iZettle, a Stockholm-based fintech startup. Notably, iZettle is a developer of small, wireless chip readers and also offers services like providing capital, invoicing and inventory management. The startup has 500K merchants on its platform which will improve PayPal’s merchant base. The deal worth $2.

BCS / Barclays Bank Plc S-8


BCS / Barclays Bank Plc FORM 6-K (Current Report of Foreign Issuer)


BCS / Barclays Bank Plc FORM 6-K (Current Report of Foreign Issuer)


Hedge funds keep cutting bets on oil rally as oil keeps rallying

2018-05-21 worldoil
NEW YORK (Bloomberg) -- As Brent oil prices climb, money managers are feeling less and less bullish.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 06738E204